Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:26:46.172Z.
Calculation as of: 2026-10-06T15:26:46.172Z.
Quote observation: 2026-10-06T15:23:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b5b90a83151b8a074e07f32cd5a8423240b7dae761ecc8f52934664174c7f924
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $35.52M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.15M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.99M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.31M | N/A | 15.63% | 9.19% | 7.93% |
| Accuray Incorporated (ARAY)vs › | $34.54M | N/A | 4.27% | 2.75% | 3.74% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.18M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.99M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $34.10M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.05M | N/A | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute